Erasca, Inc. (ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, has been one of the most volatile names in biotech over the past year. After trading near $2 in late 2025, the stock has surged roughly 490% on enthusiasm for its lead pan-RAS program, ERAS-0015. The question now is whether it can continue climbing toward the $24 level that several analysts cite as a realistic stock price target.
Erasca has broad sell-side coverage, and individual targets reveal a wide spread of opinion rather than a tight consensus. The eight attributable targets reviewed range from $20 to $33, with a calculated average of about $24.13 (rounded to a central $24 target). Notable views include J.P. Morgan at $33 (Overweight, September 2026, after a competitive pricing update), Stifel at $30 (Buy), Jefferies at $24 (Buy), Piper Sandler and H.C. Wainwright at $22 (Buy), Guggenheim at $21 (Buy), Morgan Stanley at $21 (Hold), and Bank of America Securities at $20 (Hold).
The gap between the low and high targets is driven by fundamentally different readings of the same data. Bulls argue ERAS-0015, a pan-RAS molecular glue, could be a transformative therapy across pancreatic (PDAC) and non-small cell lung cancer (NSCLC). More cautious analysts, including BofA, have argued the data "looks like a contender" but "may not be the homerun data some investors were hoping for," citing the first-mover advantage of Revolution Medicines (RVMD). BofA upgraded Erasca to Neutral from Underperform in June 2026, noting the debate had shifted from whether the drug works to whether it can matter commercially.
Erasca shares closed near $14.87 in mid-October 2026, giving the company a market capitalization of roughly $5.2 billion. Reaching $24 would require a gain of about 61% — a substantial move even for a high-beta biotech. The stock's 52-week range of $2.11 to $24.28 illustrates both the magnitude of the rally and how far the shares have pulled back from their April 2026 peak.
As a clinical-stage company, Erasca generates no meaningful revenue and posts a negative EPS (earnings per share) of roughly -$0.95 over the trailing twelve months, so traditional P/E (price-to-earnings) valuation does not apply. The path to $24 therefore depends on converting early ERAS-0015 signals into pivotal-trial progress, securing regulatory clarity, and demonstrating a commercially defensible profile against rival KRAS and pan-RAS programs.
The bull case rests on ERAS-0015's early pan-RAS activity, which triggered a wave of analyst target increases during 2026. Positive dose-escalation data from U.S. and Chinese studies, and a perception among some analysts that management has grown more confident heading into readouts, have supported higher targets. Erasca also maintains a diversified RAS/MAPK pipeline, including ERAS-4001 (a pan-KRAS inhibitor) and ERAS-12, which could extend the story beyond a single asset. A robust cash position of roughly $269 million (recent quarter) provides runway to fund near-term development.
The principal risks are clinical and competitive. If ERAS-0015's efficacy or safety profile disappoints in larger trials, or if differentiation proves insufficient against Revolution Medicines and other emerging assets, the premium now embedded in the share price could compress quickly. As a pre-revenue biotech, Erasca will likely require additional capital over time, exposing shareholders to dilution. The stock is also susceptible to binary event risk, where a single readout can drive outsized moves in either direction, and its valuation now reflects substantial future success that has not yet been proven.
The $24.28 prior high from April 2026 is the most significant overhead level: it coincides closely with the central target and represents a resistance zone where earlier buyers may look to reduce positions. The 52-week low of $2.11 sits far below the current price, while the shares trade between their longer-term moving averages. A sustained move back above the mid-teens and eventually through the prior high would signal renewed momentum, while failure to hold near-term support could invite further consolidation after the year's dramatic run.
Analyst price targets typically reflect a roughly 12-month horizon, though individual analysts may anchor their targets to specific catalysts rather than a uniform date. Key items to watch include the next quarterly earnings report (anticipated around mid-November 2026), updated ERAS-0015 clinical data and any pivotal-trial design or regulatory feedback, progress on ERAS-4001 and ERAS-12, additional analyst revisions, and financing developments. Competitive data from peer RAS/MAPK programs can also move sentiment materially.
For traders seeking a systematic view of momentum and trend across a fast-moving name like Erasca, Tickeron's AI Daily Buy/Sell Signals offers an additional layer of analysis. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. Explore the signals to see how Erasca's current technical profile compares with the broader market.
The $24 target is a credible, analyst-derived reference point — the average of eight published price targets — but it sits 61% above the latest price and reflects a bull-case interpretation of ERAS-0015's potential rather than a guaranteed outcome. The wide $20-to-$33 range underscores how divided the Street remains about the drug's commercial prospects. A move toward $24 would require favorable clinical data, sustained competitive differentiation, and continued investor appetite for high-risk biotech. Conversely, any disappointment in pivotal development or intensifying competition could keep the shares well below that level. Investors should watch the clinical calendar, financing needs, and analyst revisions as the most telling signals of which path the stock is likely to take.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with SNGX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then SNGX could also see price increases.
| Ticker / NAME | Correlation To ERAS | 1D Price Change % | ||
|---|---|---|---|---|
| ERAS | 100% | -0.66% | ||
| SNGX - ERAS | 53% Loosely correlated | +3.33% | ||
| REPL - ERAS | 42% Loosely correlated | +23.07% | ||
| AMLX - ERAS | 39% Loosely correlated | -0.81% | ||
| RZLT - ERAS | 36% Loosely correlated | +2.68% | ||
| GLUE - ERAS | 36% Loosely correlated | +1.78% | ||
More | ||||